Startup · United States
Sensible Biotechnologies
HQ ClaymontFounded 202111-50 employeesUpdated
Develops technology for manufacturing messenger RNA.
Funding5 rounds · $23.9M
- Equity raised
- $23.9M
- Debt, secondaries & grants
- Undisclosed
- Latest
- $13.5MStage undisclosed · Aug 27, 2026
| Announced | Stage | Amount | Valuation | Lead investors | Other investors | Confidence |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Undisclosed | $13.5M | — | — | — | Reported |
| Sep 4, 2025 | Grant | Undisclosed | — | — | — | Reported |
| Feb 29, 2024 | Seed | $6.2M | — | — | — | Reported |
| Apr 6, 2023 | Pre-Seed | $3.8M | — | — | — | Reported |
| Nov 17, 2021 | Pre-Seed | $420K | — | — | — | Reported |
- Undisclosed$13.5MAug 27, 2026
- GrantUndisclosedSep 4, 2025
- Seed$6.2MFeb 29, 2024
- Pre-Seed$3.8MApr 6, 2023
- Pre-Seed$420KNov 17, 2021
Raised counts equity rounds; debt, secondary sales and grants are totaled separately. Amounts in other currencies are converted at the announcement month's average rate. A ~ marks an estimated or converted amount.
People2
| Person | Role |
|---|---|
| Miroslav Gašpárek | CEO and Co-Founder |
| Marian Kupculak | CSO |
Sources4
Profile2
- 1
Defence Finance Monitor · Supports Organization · description
“Founded by Slovak innovators, the company has rapidly drawn attention for its novel approach to messenger RNA (mRNA) production. Rather”
- 2CompanySensible | Home
Sensible Biotechnologies · Supports Organization · website
“Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines”
Funding1
- 3
Supports Funding round, Organization · country, Organization · employee range, Organization · founded year, Organization · hq city, Organization · linkedin url, Organization · name, Role
“funding round: Venture Round, 2026-08-27, USD 13,518,941”
People1
- 4
sartorius.com · Supports Role
“has played a vital role in enabling global biologics manufacturing - from vaccines to gene therapies - and we are honored to work with them to build the industrial backbone to unlock the next generation of mRNA therapeutics,” said Miroslav Gašpárek, CEO and Co-Founder of Sensible Biotechnologies.”
Each fact on this page is attached to the sources that support it. Archived copies are linked when we keep one.